Form 4: Theravance Biopharma SVP Rhonda Farnum Reports Stock Sale

Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, sold 4,000 ordinary shares at $9 per share on April 21, 2025, according to a Form 4 filing.

Summary

• Rhonda Farnum, a Senior Vice President at Theravance Biopharma, reported a transaction involving the company's ordinary shares.
• On April 21, 2025, Ms. Farnum sold 4,000 shares at a price of $9 per share.
• Following the transaction, Ms. Farnum beneficially owns 370,038 ordinary shares directly.
• The sale was executed under a pre-arranged 10b5-1 trading plan established on March 14, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The transaction was pre-planned under a 10b5-1 plan, so it doesn't necessarily reflect a change in the insider's view of the company's prospects.

Industry Context

Insider transactions are routinely monitored by investors to gauge sentiment about a company's prospects. Sales don't necessarily indicate a negative outlook, especially when executed under pre-arranged trading plans like a 10b5-1 plan.

Stakeholder Impact

• The stock sale could have a minor impact on shareholder sentiment, but the pre-planned nature of the transaction mitigates potential concerns.

Key Dates

Keywords

Form 4, Theravance Biopharma, TBPH, Insider Trading, Stock Sale, Rhonda Farnum, 10b5-1 plan, Ordinary Shares